Relapsed Refractory clinical trials

Explore recruiting relapsed refractory clinical trials.

Recruiting relapsed refractory studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II trial investigating MOsunetuzumab and ZAnubrutinib (BGB-3111) in Relapsed/refracTory follicular lymphoma patients (MOZART)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

France, Norway, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Czechia, Greece, Germany, Poland, France, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL

Italy, Germany, Spain, Netherlands, France, Romania +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in patients with relapsed/refractory CLL - (CLL2-BZAG)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed Refractory trials by city

Relapsed Refractory in Toronto Relapsed Refractory in Vancouver Relapsed Refractory in Montreal Relapsed Refractory in Calgary Relapsed Refractory in Edmonton Relapsed Refractory in Ottawa Relapsed Refractory in Winnipeg Relapsed Refractory in Quebec City Relapsed Refractory in Hamilton Relapsed Refractory in Kitchener Relapsed Refractory in London Relapsed Refractory in Halifax Relapsed Refractory in New York Relapsed Refractory in Los Angeles Relapsed Refractory in Chicago Relapsed Refractory in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease